Clik here to view.
ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy...
TOKYO & BASKING RIDGE, N.J. Daiichi Sankyo (TSE: 4568) and AstraZeneca’s (LSE/STO/Nasdaq: AZN) ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been approved in the U.S. for the treatment of adult...
View ArticleClik here to view.
Delta-Fly Pharma Inc.: Notice of Authorization to Conduct the Phase I/II...
TOKUSHIMA, Japan Following to the previous information on March 11th, 2024, we are excited to share our latest development status. We are pleased to announce the protocol for the Phase I/II clinical...
View ArticleClik here to view.
Propanc Biopharma’s CEO Shares Views on Revolutionizing Cancer Treatment: An...
MELBOURNE, Australia Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and...
View ArticleClik here to view.
Ferronova – Nanoparticle Trial Begins in Patients With Gastric and...
ADELAIDE, Australia Australian biotech company Ferronova has announced the initiation of a clinical trial of the company’s FerroTrace® nanoparticle technology in patients with gastric and...
View ArticleClik here to view.
Neuboron Medical Group Advances Cancer Treatment: Introducing Next-Generation...
NANJING, China Neuboron Medical Group (Neuboron) is pleased to announce significant progress in the commercialization of its comprehensive Boron Neutron Capture Therapy (BNCT) solution, marking a...
View ArticleClik here to view.
Crown Bioscience Achieves CAP 15189 Accreditation; ISO 15189 Standard for...
SAN DIEGO & HAMBURG, Germany & SUZHOU, China Crown Bioscience, a leading global contract research organization (CRO) and a JSR Life Sciences company, today announced the dual attainment of...
View ArticleClik here to view.
First Interim Analysis of PROSPER Study Details Patient-Reported Symptom...
TOKYO On Friday, 12th April, 2024, Professor Julia Scarisbrick of University of Birmingham presented interim findings from the Kyowa Kirin, Inc. (Kyowa Kirin, TSA: 4151)-sponsored study, “Real-World...
View ArticleClik here to view.
佐賀大学とBostonGeneがEGFR陽性肺癌患者におけるICIの治療効果予測因子を特定するための新規バイオマーカー探索を目的とした研究を発表
WALTHAM, Mass. （ビジネスワイヤ） — 2024年4月16日、佐賀大学医学部附属病院はBostonGene（本社：米国マサチューセッツ州ウォルサム）との間で上皮成長因子受容体（EGFR）陽性肺癌患者における免疫チェックポイント阻害剤（ICI）の治療効果予測因子のバイオマーカー研究を推進することで合意しました。...
View ArticleClik here to view.
BostonGene and Saga University Announce Collaboration to Uncover Biomarkers...
WALTHAM, Mass. BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, and Saga University located in Saga, Japan and known for its commitment to educating and training...
View ArticleClik here to view.
ESCMID Global 2024: Shionogi presents real-world data demonstrating efficacy...
OSAKA, Japan Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President & CEO: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) announces new data from the largest European real-world evidence...
View ArticleClik here to view.
Rubedo Life Sciences完成了由Khosla Ventures和Ahren Innovation Capital领投的4000万美元A轮融资
加利福尼亚州, 桑尼维尔 (美国商业资讯)– Rubedo Life Sciences是一家生物制药公司，致力于开发针对驱动与年龄相关疾病的老化细胞的首创疗法，今日宣布完成了4000万美元的A轮融资。本轮融资由Khosla Ventures和Ahren Innovation Capital领投，Hevolution、R42、Modi Ventures、Cerigo...
View ArticleClik here to view.
ルベド・ライフ・サイエンシズ、コスラ・ベンチャーズとアーレン・イノベーション・キャピタル主導の4,000万ドルのシリーズA資金調達を完了
カリフォルニア州サニーベール （ビジネスワイヤ） —...
View ArticleClik here to view.
Ochre Bio宣布与Boehringer Ingelheim合作，为晚期肝病患者开发新型再生疗法
英国牛津 (美国商业资讯)– 慢性肝病药物开发领域的先驱Ochre Bio今天宣布与Boehringer Ingelheim建立合作伙伴关系，将专注于研究和开发治疗慢性肝病(CLD)，例如晚期代谢性脂肪肝炎(MASH)肝硬化的第一线创新再生疗法。 根据这一合作伙伴关系，Ochre...
View ArticleClik here to view.
BeiGene Receives European Commission Approval for Tislelizumab as Treatment...
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the European Commission (EC) has...
View ArticleClik here to view.
HighField Biopharmaceuticals Announces Two Abstracts Accepted for the 2024...
HANGZHOU, China HighField Biopharmaceuticals, a clinical stage immuno-oncology company using lipid-based therapeutics to treat cancer, announced today that two HighField abstracts have been accepted...
View ArticleClik here to view.
Global Oncology Innovator BeiGene Highlights New Data across Hematology and...
BASEL, Switzerland & BEIJING & CAMBRIDGE, Mass. BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will share research outcomes from its...
View ArticleClik here to view.
Parse Biosciences与Hamilton、Opentrons Labworks和SPT Labtech合作推出实验室自动化供应商计划
西雅图 (美国商业资讯)– 领先的易用型可扩展单细胞测序解决方案提供商Parse Biosciences今天宣布，该公司已推出实验室自动化提供商计划，使自动化提供商能够随时支持Parse的Evercode™单细胞产品的应用。通过将功能强大的自动化技术与Parse Evercode平台相结合，客户将获得前所未有的高通量单细胞测序能力，使他们能够迅速为大规模研究生成洞察。...
View ArticleClik here to view.
パース・バイオサイエンシズが研究室用自動化プロバイダー・プログラムをローンチし、ハミルトン、オープントロンズ、ラボワークス、SPTラボテックと提携
SEATTLE （ビジネスワイヤ） — アクセスが容易で拡張性に優れたシングルセル・シーケンシング・ソリューションの大手プロバイダーであるパース・バイオサイエンシズ（パース）は、研究室用自動化プロバイダー・プログラムのローンチを発表しました。このプログラムにより、自動化プロバイダーは当社のEvercode™シングルセル製品の導入を簡単にサポートできるようになります。強力な自動化とParse...
View ArticleClik here to view.
Inocras Pioneers Precision Health with Revolutionary Whole Genome Insights
SAN DIEGO Inocras, a leading AI-driven whole genome testing company, proudly announces the launch of CancerVision and RareVision, its flagship whole genome diagnostics solutions in solid tumor...
View ArticleClik here to view.
Avistone Announces the Approval of Vebreltinib as the First MET-TKI Treatment...
BEIJING Beijing Avistone Biotechnology Co., Ltd. (also referred to as Avistone Biotechnology or Avistone), an innovative biotechnology company focused on precision oncology therapeutics, announced...
View Article